ImmunoGenesis Announces the Formation of Scientific Advisory Board Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies HOUSTON, July 01,…
Read More
Kayothera Named as a Winner of the American Diabetes Association’s Innovation Challenge to Transform Type 2 Diabetes Care Seattle, WA — June 21, 2025, Kayothera, Inc., a preclinical-stage therapeutics company pioneering first-in-class, oral inhibitors of the retinoid nuclear receptor pathway, today announced that it has been recognized as one of the…
Read More
Bainbridge Health Welcomes B. Braun to the National Infusion Collaborative™ Bainbridge Health announced that B. Braun Medical Inc. (B. Braun) has joined the National Infusion Collaborative (NIC) PHILADELPHIA, PA, UNITED STATES, June 10, 2025 /EINPresswire.com/ -- Bainbridge Health, a leading provider of medication safety and stewardship solutions, today announced that…
Read More
Latus Bio Strengthens Executive Team with Appointments of Ainslie Little as COO and Katie Hewitt as interim CBO BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company driving advances in AAV gene therapy, announces the appointments of Ainslie Little, PhD, as COO and Katie Hewitt, as interim CBO. “These appointments reflect…
Read More
Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting Trial is evaluating VIPER-101, a novel, gene-edited, autologous dual-population CAR-T therapy in patients with T-cell lymphoma PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics Inc., a clinical-stage immunotherapy company specializing in the development of innovative…
Read More
Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene…
Read More
Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research manuscript in Nature Communications: “Optimized AAV capsids for basal…
Read More
Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, “AAVs engineered for robust brain transduction drive therapeutically relevant expression of secreted recombinant…
Read More
Source: Cancer Focus Fund ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Promising early signals of activity seen as…
Read More
Latus Bio Announces Multiple Oral and Poster Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting PHILADELPHIA--(BUSINESS WIRE)--Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy (ASGCT)…
Read More
Strados Labs Introduces Grant Initiative to Accelerate Research into Continuous Lung Sound Monitoring The new program provides eligible research studies with in-kind support for the use of the RESP® Biosensor system. by Strados Labs | Mar 25, 2025 | Press Releases Philadelphia, PA, March 20, 2025 – Strados Labs, a medical technology company, is…
Read More
ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of…
Read More
BioAdvance Capital Fuels Life Sciences Innovation with Nine New Investments Expands Portfolio with Cutting-Edge Innovations in Gene Therapy, AI-Driven Drug Discovery, and Precision Medicine and Reaffirms Investments in Existing Portfolio Philadelphia, PA – February 25, 2025 – In 2024, BioAdvance Capital continued its mission to foster early-stage healthcare innovation in…
Read More
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug candidate at the 20th Annual CHDI Huntington’s Disease (HD) Therapeutics…
Read More
Strados Labs Collaborates with Beth Israel Deaconess Medical Center for Innovative Study in Pulmonary Edema The study will evaluate continuous lung sound monitoring for the early detection of pulmonary edema and prevention of complications in critically ill ICU patients. by Strados Labs | Feb 20, 2025 | Press Releases Philadelphia, PA, February 20, 2025 —…
Read More
IVIEW Therapeutics Announces Topline Results from Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe for Dry Eye Disease CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical trial evaluating 2 concentrations…
Read More
The New Yorker: The Long Quest for Artificial Blood One of the most valuable substances in the world has never been replicated. Are we close? By Nicola Twilley See more here
Read More
Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™ Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programs DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced its…
Read More
IVIEW Therapeutics Completed A++ Round Financing to Advance its innovative Ocular Drug Development Programs IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced the successful completion of its A++ round of financing. The funds raised will primarily be used to advance IVIEW’s…
Read More
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies Publication reports 10% of participants wereither "Much Improved" or "Very Much Improved" as rated by the Clinician Global…
Read More